This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1078155208097632v1 15/2/119    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dasanu, C. A. Articles by Alexandrescu, D. T. Search for Related Content PubMed PubMed Citation Articles by Dasanu, C. A. Articles by Alexandrescu, D. T. Social Bookmarking                         What's this?

Acute retinal pigment epithelial detachment secondary to pamidronate administration

¹ Practicing Medical Oncologist, Seattle, WA
² Georgetown University, Washington, DC

^* To whom correspondence should be addressed.

	Abstract

Bisphosphonates are associated with an important number of inflammatory ocular side-effects including but not limited to conjunctivitis, episcleritis, scleritis, uveitis, and optic neuritis. The intravenous bisphosphonates appear to be linked with more severe ocular inflammation than the orally administered ones. These eye complications tend to resolve with the bisphosphonate discontinuation and can re-occur with its re-challenge. We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer.

Key Words: intravenous bisphosphonate, pamidronate, ocular inflammation, macular degeneration, retinal pigment epithelial detachment.

First published on September 25, 2008, doi:10.1177/1078155208097632

Journal of Oncology Pharmacy Practice 2009;15:119.

A more recent version of this article appeared on June 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?